Profile of the VERSANT HCV genotype 2.0 assay

Yang, Ruifeng; Wei, Lai

doi:10.1080/14737159.2018.1541740

Cited by 6 publications

(7 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…104 The most widely used, CE-IVD-marked method is based on reverse hybridisation with the second-generation line probe assay. 105 A commercial CE-IVD-marked assay based on deep sequencing is also available. 106,107 Recently, distinct subtypes of genotypes 1 to 8 that are infrequent in Europe, North America, Japan and Australia (defined as genotype 1 non-1a/1b, genotype 2 non-2a/2b, genotype 3 non-3a, genotype 4 non-4a/4d, and subtypes of genotypes 5 to 8) have been shown to be highly prevalent in certain regions of Africa and Asia and in migrants from these regions.…”

Section: Hcv Genotype Determinationmentioning

confidence: 99%

“…Reverse hybridisation with the line probe assay accurately identifies only genotypes 1 to 6 and subtypes 1a and 1b, but misclassifies most of these infrequent, less treatment-susceptible subtypes. 105 Their accurate determination requires sequence analysis of the NS5B or another coding region of the HCV genome followed by phylogenetic analysis. A commercial CE-IVD-marked assay based on deep sequencing can be used for this purpose, but it requires specific equipment and skills.…”

Section: Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Pawlotsky¹,

Negro²,

Aghemo³

et al. 2020

Journal of Hepatology

865

632

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.

show abstract

Section: Hcv Genotype Determinationmentioning

confidence: 99%

Section: Recommendationsmentioning

confidence: 99%

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Pawlotsky¹,

Negro²,

Aghemo³

et al. 2020

Journal of Hepatology

865

632

View full text Add to dashboard Cite

show abstract

“…First, NS3 and NS4 proteins were also used in anti-HCV assays. Their sequences among different genotypes were not compared in the present study, because NS3 and NS4 proteins are far less conserved than the core priotein [20],and the high sequence diversity will greatly increase the experimental complexity. Second, we failed to evaluate the sensitivity for genotypes 4 and 5, which are confined in several countries in the Middle East and Africa but seldom seen in the other regions around the world [1].…”

Section: Discussionmentioning

confidence: 99%

“…Samples with confirmed positive anti-HCV results were first genotyped using an in-house assay based on polymerase chain reaction and Sanger sequencing [19, 20]. Briefly, the core sequence was amplified.…”

Section: Methodsmentioning

confidence: 99%

A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?

et al. 2019

View full text Add to dashboard Cite

Recent advance in the direct-acting antivirals (DAAs) offers the potentials to eradicate hepatitis C virus (HCV) worldwide and makes universal screening more urgent. A point-of-care (POC) oral anti-HCV assay, the Fortune assay, was developed and its performance was evaluated. Individuals with or without HCV infection were recruited in three Centers. Paired oral and serum samples were tested using the Fortune and InTec anti-HCV assays. The Kehua serum anti-HCV assay served as a supplemental test to verify the discordant results. Some oral samples were also tested using the OraQuick anti-HCV assay. Furthermore, the Fortune assay results were compared with the documented RNA results. Sensitivity, specificity, and accuracy of the Fortune assay was 93.11%, 98.48%, and 96.58%, respectively (n = 1,022). Consistency between the Fortune and OraQuick assays was 96.35% (264/274); the Fortune assay detected additional 8 positive oral samples missed by the OraQuick assay. The Fortune assay demonstrated a 97.46% (115/118) positivity among the viremic patients. Furthermore, its sensitivity was HCV genotype independent. In conclusion, the Fortune assay was highly specific and accurate. It had comparable sensitivity as the serum assays for the diagnosis of active HCV infection. It provides a completely non-invasive and reliable tool for HCV screening in the DAA era.

show abstract

“…Another method used for genotyping is genotypespecific real-time PCR and sequencing-based assays (55). The development of real-time PCR (qPCR)-based assays has enhanced viral load analysis and detection.…”

Section: Commercial Assaysmentioning

confidence: 99%

Hepatitis C: A Review on Current and Emerging Genotyping Assays

Mohd Amin,

Mat Jusoh,

Irekeola

et al. 2023

MJMHS

View full text Add to dashboard Cite

Hepatitis C is a global public health concern that infects millions of people worldwide. The continual discovery of new genotypes and subtypes of hepatitis C virus (HCV) is an indication of a persistent molecular evolution of the virus. This remains a concern in the efforts towards hepatitis C elimination, as effective management of the disease is, in part, dependent on the HCV genotype responsible for the infection. Accurate HCV screening and quantification using rapid but highly sensitive and reliable methods are crucial for the diagnosis and subsequent management of HCV-related diseases. Thus, this article discusses HCV and the common methods employed for HCV detection and genotyping. While nucleotide sequencing and phylogenetic analysis of core/E1 and NS5B region are regarded as the gold standard and the most recommended method used for HCV genotyping, electrochemical sensors are being explored for their rapidity.

show abstract

Profile of the VERSANT HCV genotype 2.0 assay

Cited by 6 publications

References 94 publications

EASL recommendations on treatment of hepatitis C: Final update of the series☆

EASL recommendations on treatment of hepatitis C: Final update of the series☆

A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?

Hepatitis C: A Review on Current and Emerging Genotyping Assays

Contact Info

Product

Resources

About